Research programme: kinase inhibitors - Daiichi Sankyo/Teva Pharmaceutical Industries
Alternative Names: CEP-17940; CEP-18050; CEP-28122; CEP-31933; CEP-40783; CEP-4416; CEP-7055; CEP-A; RXDX-106Latest Information Update: 28 Dec 2021
At a glance
- Originator Ambit Biosciences Corporation; Cephalon
- Developer Daiichi Sankyo Company; Ignyta; Teva Pharmaceutical Industries
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (PO)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 29 Dec 2017 US FDA approves IND application for RXDX 106 in Solid tumours (Late-stage disease, Metastatic disease)